+830.2%
COHR vs MRNA
+34.8%
+795.4%
-54.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.2% | +5.4% | -1.2% | +3.9% |
| 7D | +8.3% | -1.1% | +9.4% | +8.4% |
| 30D | -14.1% | +126.1% | -140.3% | -20.4% |
| 3M | -16.0% | +190.0% | -206.0% | -28.2% |
| 6M | +21.5% | +157.2% | -135.8% | +6.5% |
| YTD | +65.4% | +388.2% | -322.7% | +21.2% |
| 1Y | +195.0% | +467.0% | -272.0% | +105.8% |
| 3Y | +830.2% | +36.1% | +794.1% | +710.1% |
| All | +830.2% | +34.8% | +795.4% | +710.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling